-
Humira biosimilars falter in disrupting the market
Numerous Humira biosimilars are on the market after AbbVie's 20-year exclusive on the rheumatoid arthritis biologic, but they aren't fostering much competition, KFF Health News reported Sept. 19. -
FDA raises safety issue in generic organ anti-rejection drug
The FDA reduced its therapeutic equivalence rating in Accord Healthcare's tacrolimus oral capsules because of safety concerns, but the generic's approval remains, the agency said Sept. 19. -
Bausch Health CFO resigns
Tom Vadaketh, executive vice president and CFO of pharmaceutical company Bausch Health Cos., has resigned from his role and will be leaving the company effective Oct. 13. -
‘It’s never too late to start’: How a supported journey in specialty pharmacy services transforms hospital + health system finances and care delivery
Over the last few years, “doing more with less” has become a mantra for most hospitals and health systems. Many are now looking at specialty pharmacy services as a way to strengthen their financial portfolios, reduce administrative burden and deliver more patient-centered care. -
15 pharmacists in hospital C-suite, top leadership roles
Besides filling the chief pharmacy officer and pharmacy director roles, pharmacists are filling other C-suite and senior leadership jobs in hospitals. -
Ozempic, Wegovy shortages could last years
The shortages of Novo Nordisk's Ozempic and Wegovy, a Type 2 diabetes and weight loss drug, respectively, could continue for years, Forbes reported Sept. 16. -
6 drugs now in shortage
Since late August, six medications have fallen into short supply, including one cancer therapy. -
MDMA therapy reduces PTSD symptoms in phase 3 study
The potential is growing for MDMA-assisted therapy, also known as ecstasy, to be approved for treating PTSD as more research finds success. -
FDA to weigh public comments before making decision on common decongestant
Following an FDA advisory committee's determination that a common ingredient in over-the-counter cough and cold medicines is ineffective, the agency released a statement clarifying it has not yet made a final decision on the matter. -
FTC cracks down on improper drug patent filings
The Federal Trade Commission is targeting brand-name drugmakers that are improperly listing patents, which can weaken competition. -
New COVID vaccines aren't boosters, experts say
The updated fall COVID-19 vaccines that are beginning to roll out are not booster shots. Experts say there is an important distinction between what constitutes a booster shot and these newly formulated vaccines, CBS News reported Sept. 15. -
Local PBM market is dwindling, AMA finds
Six pharmacy benefit managers account for 96 percent of the industry's market share, and their lead is growing, according to an analysis from the American Medical Association. -
J&J rebrands, cuts script logo
Johnson & Johnson is reinventing itself by renaming its pharmaceutical segment and changing its logo, the company said Sept. 14. -
Mount Sinai gets $13M to create next-gen coronavirus vaccines
The National Institutes of Health has awarded New York City-based Icahn School of Medicine at Mount Sinai a five-year, $13 million grant to develop new coronavirus vaccines. -
CMS adds 34 drugs to list of Medicare savings
CMS has named 34 prescription drugs that could have lower out-of-pocket costs for those on Medicare, potentially saving up to $618 per dose. -
U of Wisconsin offers PharmD pathway for high schoolers, undergrads
The University of Wisconsin-Madison's pharmacy school unveiled a new avenue that guarantees admission for high schoolers and first-year undergrads into its PharmD program. -
California found 'major deficiencies' at hospital pharmacy on probation
The California State Board of Pharmacy documented "major deficiencies" related to staff training and knowledge in 2019 at Sutter Coast Hospital's compounding pharmacy, which was recently placed on a three-year probation. -
50 drugs at Mark Cuban's pharmacy with biggest cost reductions
In 2023, Mark Cuban Cost Plus Drug Co. began selling two generic medications cheaper than their branded versions by more than $10,000. -
FDA warns CVS, Walgreens against selling unapproved eye products
The FDA sent warning letters Sept. 12 to CVS, Walgreens and six other companies for illegally marketing unapproved eye drug products. -
1 cancer drug in shortage nearing 100% resupply, White House says
Cisplatin, a drug used for multiple types of cancer that's been in a severe shortage for months, is close to returning to 100 percent of pre-shortage supply levels, the White House said Sept. 12.
Page 26 of 50